SCHEMBL198164

SCHEMBL198164

Cc1nc2cc(C(F)(F)F)ccn2c1-c1csc(C2(c3ccc(C(=O)NO)cc3)CCOCC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.38
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
HDAC6 Q9UBN7 5/20 0.35
HDAC1 Q13547 5/20 0.35
HDAC7 Q8WUI4 4/20 0.35
HDAC8 Q9BY41 4/20 0.35
HDAC3 O15379 4/20 0.35
HDAC2 Q92769 4/20 0.35
HDAC4 P56524 3/20 0.35
HDAC9 Q9UKV0 3/20 0.35
HDAC5 Q9UQL6 3/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33
CNR2 P34972 1/20 0.33
LRRK2 Q5S007 1/20 0.33
SYK P43405 1/20 0.33
KDM4E B2RXH2 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354088 0.94 HDAC6 (0.36) HDAC6HDAC1HDAC7HDAC8HDAC3
SCHEMBL3355103 0.93 AKT1 (0.36) HDAC6HDAC1HDAC7HDAC8HDAC3
SCHEMBL199623 0.89 KCNH2 (0.37) KCNH2RAF1BRAFHDAC6HDAC1
SCHEMBL197843 0.89 HDAC1 (0.41) KCNH2RAF1BRAFHDAC6HDAC1
SCHEMBL196935 0.88 KCNH2 (0.40) KCNH2HDAC6HDAC1HDAC7HDAC8
SCHEMBL197259 0.87 KCNH2 (0.38) KCNH2HDAC6HDAC1HDAC7HDAC8
SCHEMBL198176 0.87 F2RL3 (0.39) KCNH2HDAC6HDAC1HDAC7HDAC8
SCHEMBL197698 0.87 AKT1 (0.40) KCNH2HDAC6HDAC1HDAC7HDAC8
SCHEMBL197443 0.85 CDK2 (0.44) KCNH2HDAC6HDAC1HDAC7HDAC8
SCHEMBL197571 0.85 KCNH2 (0.40) KCNH2HDAC6HDAC1HDAC7HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US claimed
JP-2011529504-A 2011-12-08 JP claimed
EP-2326622-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2011-06-01 EP claimed
WO-2010014611-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-02-04 WO claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 KCNH2 4061/4885RAF1 2334/4885BRAF 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.